Upstream Bio, Inc. (UPB) reported a quarterly loss of $0.75 per share on May 10, 2026, exceeding the Zacks Consensus Estimate of a loss of $0.80, while also marking an increase from a loss of $0.51 per share in the previous year. The company’s revenues for the quarter reached $1.03 million, surpassing estimates by 102.75% and showing significant growth from $0.57 million year-over-year.
The company’s performance has been volatile, with UPB shares down approximately 67% since the start of the year, compared to an S&P 500 gain of 8.1%. Over the past four quarters, UPB has exceeded earnings estimates twice. The upcoming earnings call is anticipated to provide more insights into future expectations.
The current consensus EPS estimate for the next quarter stands at -$0.79 with revenues projected at $0.51 million. In the broader context, the Medical – Biomedical and Genetics sector is currently ranked in the bottom 41% of Zacks industries, which could influence UPB’s stock performance moving forward.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
